Miguel Medina

List of Publications by Year
in descending order

104 papers	8,171 citations	57758 44 h-index	51608 86 g-index
115 all docs	115 docs citations	115 times ranked	10418 citing authors

#	Article	IF	Citations
1	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
2	Polymerization of Ï„ into Filaments in the Presence of Heparin: The Minimal Sequence Required for Ï„ â€•Ï„ Interaction. Journal of Neurochemistry, 1996, 67, 1183-1190.	3.9	352
3	Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology, 2004, 167, 953-960.	5.2	308
4	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	3.8	299
5	New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidatesâ€"Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 2012, 20, 127-150.	3.9	285
6	What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathologica Communications, 2017, 5, 99.	5.2	272
7	Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport, 1997, 8, 2085-2090.	1.2	258
8	WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nature Cell Biology, 2001, 3, 484-491.	10.3	251
9	Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study. Journal of Alzheimer's Disease, 2012, 33, 205-215.	2.6	248
10	An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Frontiers in Neuroscience, 2018, 12, 464.	2.8	247
11	Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport, 1997, 8, 1489-1494.	1.2	233
12	RhoA/ROCK regulation of neuritogenesis via profilin IIaâ€"mediated control of actin stability. Journal of Cell Biology, 2003, 162, 1267-1279.	5.2	209
13	Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors:â€‰ New Disease-Modifying Agents for Alzheimer's Disease. Journal of Medicinal Chemistry, 2005, 48, 7223-7233.	6.4	203
14	Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3Î² by Tideglusib. Journal of Biological Chemistry, 2012, 287, 893-904.	3.4	190
15	Î´-catenin, an Adhesive Junctionâ€"associated Protein Which Promotes Cell Scattering. Journal of Cell Biology, 1999, 144, 519-532.	5.2	185
16	Hemizygosity of Î´-Catenin (CTNND2) Is Associated with Severe Mental Retardation in Cri-du-Chat Syndrome. Genomics, 2000, 63, 157-164.	2.9	168
17	Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications, 2017, 5, 91.	5.2	157
18	MicroRNAs in Neurodegenerative Diseases. International Review of Cell and Molecular Biology, 2017, 334, 309-343.	3.2	151

#	Article	IF	Citations
19	The Two Species of the Foot-and-Mouth Disease Virus Leader Protein, Expressed individually, Exhibit the Same Activities. Virology, 1993, 194, 355-359.	2.4	147
20	Donepezilâ€“tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorganic and Medicinal Chemistry, 2005, 13, 6588-6597.	3.0	145
21	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
22	The role of extracellular Tau in the spreading of neurofibrillary pathology. Frontiers in Cellular Neuroscience, 2014, 8, 113.	3.7	130
23	Manzamine B and E and Ircinal A Related Alkaloids from an IndonesianAcanthostrongylophoraSponge and Their Activity against Infectious, Tropical Parasitic, and Alzheimer's Diseases. Journal of Natural Products, 2006, 69, 1034-1040.	3.0	129
24	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structureâ€“Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimerâ€™s Disease. Journal of Natural Products, 2007, 70, 1397-1405.	3.0	123
25	An Overview on the Clinical Development of Tau-Based Therapeutics. International Journal of Molecular Sciences, 2018, 19, 1160.	4.1	120
26	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1549-1556.	4.8	116
27	Deconstructing GSK-3: The Fine Regulation of Its Activity. International Journal of Alzheimer's Disease, 2011, 2011, 1-12.	2.0	113
28	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
29	Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO Journal, 2005, 24, 1706-1716.	7.8	105
30	New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochemical Pharmacology, 2014, 88, 540-547.	4.4	101
31	Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Frontiers in Molecular Neuroscience, 2011, 4, 24.	2.9	95
32	Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture. Virus Research, 1992, 26, 113-125.	2.2	84
33	Drosophila cathepsin B-like proteinase: A suggested role in yolk degradation. Archives of Biochemistry and Biophysics, 1988, 263, 355-363.	3.0	81
34	Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2790-2798.	1.9	80
35	Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 52, 271-281.	2.6	77
36	?-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development. Journal of Comparative Neurology, 2000, 420, 261-276.	1.6	68

#	Article	IF	Citations
37	New Features about Tau Function and Dysfunction. Biomolecules, 2016, 6, 21.	4.0	67
38	C455R <i>notch3</i> mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology, 2002, 59, 277-279.	1.1	62
39	RIPped out by presenilin-dependent Î³-secretase. Cellular Signalling, 2003, 15, 829-841.	3.6	59
40	A Î´-Catenin Signaling Pathway Leading to Dendritic Protrusions. Journal of Biological Chemistry, 2008, 283, 32781-32791.	3.4	58
41	Evidence for a new binding mode to GSK-3: Allosteric regulation by the marine compound palinurin. European Journal of Medicinal Chemistry, 2013, 60, 479-489.	5.5	57
42	Presenilin Affects Arm/Î²-Catenin Localization and Function in Drosophila. Developmental Biology, 2000, 227, 450-464.	2.0	51
43	Brain armadillo protein ?-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. Journal of Neuroscience Research, 2002, 67, 618-624.	2.9	51
44	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. Acta Neuropathologica Communications, 2019, 7, 31.	5.2	49
45	Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin). FEBS Letters, 1995, 372, 65-68.	2.8	44
46	Potent Î²-Amyloid Modulators. Neurodegenerative Diseases, 2008, 5, 153-156.	1.4	42
47	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. Biomolecules, 2019, 9, 734.	4.0	41
48	New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2014, 18, 69-77.	3.4	39
49	Expression of Presenilin 1 in nervous system during rat development. Journal of Comparative Neurology, 1999, 410, 556-570.	1.6	37
50	Further understanding of tau phosphorylation: implications for therapy. Expert Review of Neurotherapeutics, 2015, 15, 115-122.	2.8	37
51	Residence, Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid. Gerontology, 2021, 67, 281-289.	2.8	36
52	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
53	The in vitro formation of recombinant Ï„ polymers. Molecular and Chemical Neuropathology, 1996, 27, 249-258.	1.0	33
54	The role of tau phosphorylation in transfected COS-1 cells. Molecular and Cellular Biochemistry, 1995, 148, 79-88.	3.1	32

#	Article	IF	Citations
55	Bi-directional genetic modulation of GSK-3Î² exacerbates hippocampal neuropathology in experimental status epilepticus. Cell Death and Disease, 2018, 9, 969.	6.3	32
56	Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Current Opinion in Drug Discovery & Development, 2008, 11, 533-43.	1.9	32
57	Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD. Journal of Molecular Neuroscience, 2006, 30, 85-88.	2.3	31
58	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. PLoS ONE, 2019, 14, e0210864.	2.5	31
59	The Maternal Origin of Acid Hydrolases in Drosophila and Their Relation with Yolk Degradation. (Drosophila/acid hydrolases/developmental regulation/yolk degradation/mitochondria). Development Growth and Differentiation, 1989, 31, 241-247.	1.5	29
60	Understanding the relationship between GSK-3 and Alzheimerâ€™s disease: a focus on how GSK-3 can modulate synaptic plasticity processes. Expert Review of Neurotherapeutics, 2013, 13, 495-503.	2.8	28
61	Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. Journal of Virology, 1994, 68, 4557-4564.	3.4	28
62	Use of Okadaic Acid to Identify Relevant Phosphoepitopes in Pathology: A Focus on Neurodegeneration. Marine Drugs, 2013, 11, 1656-1668.	4.6	27
63	Additional mechanisms conferring genetic susceptibility to AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 138.	3.7	27
64	Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2011, 6, 20-30.	0.9	25
65	Toward common mechanisms for risk factors in Alzheimer's syndrome. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 571-578.	3.7	23
66	The need for better AD animal models. Frontiers in Pharmacology, 2014, 5, 227.	3.5	21
67	A serine proteinase in Drosophila embryos: Yolk localization and developmental activation. Insect Biochemistry, 1989, 19, 687-691.	1.8	19
68	Strong buffering capacity of insect cells. Implications for the baculovirus expression system. Cytotechnology, 1995, 17, 21-26.	1.6	15
69	Clinical Relevance of Specific Cognitive Complaints in Determining Mild Cognitive Impairment from Cognitively Normal States in a Study of Healthy Elderly Controls. Frontiers in Aging Neuroscience, 2016, 8, 233.	3.4	14
70	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. Biomolecular Concepts, 2018, 9, 1-11.	2.2	14
71	A Longitudinal FDG-PET Study of Transgenic Mice Overexpressing GSK- 3β in the Brain. Current Alzheimer Research, 2014, 11, 175-181.	1.4	13
72	Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection. CNS and Neurological Disorders - Drug Targets, 2011, 10, 208-214.	1.4	13

#	Article	IF	Citations
73	Wnt-1 expression in PC12 cells induces exon 15 deletion and expression of L-APP. Neurobiology of Disease, 2004, 16, 59-67.	4.4	12
74	NP7 protects from cell death induced by oxidative stress in neuronal and glial midbrain cultures from parkin null mice. FEBS Letters, 2009, 583, 168-174.	2.8	9
75	Effects of commonly prescribed drugs on cognition and mild cognitive impairment in healthy elderly people. Journal of Psychopharmacology, 2019, 33, 965-974.	4.0	9
76	Effects of Thioflavin T and GSK-3 Inhibition on Lifespan and Motility in a Caenorhabditis elegans Model of Tauopathy. Journal of Alzheimer's Disease Reports, 2019, 3, 47-57.	2.2	9
77	Protein kinases involved in the phosphorylation of human tau protein in transfected COS-1 cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1316, 43-50.	3.8	8
78	Is Tau a Prion-Like Protein?. Journal of Alzheimer's Disease, 2014, 40, S1-S3.	2.6	8
79	Longitudinal Assessment of a Transgenic Animal Model of Tauopathy by FDG-PET Imaging. Journal of Alzheimer's Disease, 2014, 40, S79-S89.	2.6	8
80	EuroTau: towing scientists to tau without tautology. Acta Neuropathologica Communications, 2017, 5, 90.	5.2	8
81	Prodromal Alzheimerâ€™s Disease: Constitutive Upregulation of Neuroglobin Prevents the Initiation of Alzheimerâ€™s Pathology. Frontiers in Neuroscience, 2020, 14, 562581.	2.8	8
82	Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins. Vaccines, 2020, 8, 127.	4.4	8
83	Discussion. Plastic and Reconstructive Surgery, 2012, 129, 835-837.	1.4	7
84	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study. Journal of Personalized Medicine, 2021, 11, 1318.	2.5	7
85	Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors. MedChemComm, 2014, 5, 474-488.	3.4	6
86	Long runs of homozygosity are associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 142.	4.8	6
87	The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimerâ€™s Disease. , 0, , .		4
88	Tau Assembly into Filaments. Methods in Molecular Biology, 2018, 1779, 447-461.	0.9	4
89	Detecting Circulating MicroRNAs as Biomarkers in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2018, 1779, 471-484.	0.9	4
90	P4-428 TDZDS: GSK3Î² inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. Neurobiology of Aging, 2004, 25, S596.	3.1	3

#	Article	IF	Citations
91	Protocols for Monitoring the Development of Tau Pathology in Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 143-160.	0.9	3
92	A Novel Neuroprotection Target With Distinct Regulation in Stroke and Alzheimerâ€™s Disease. , 2017, , 123-147.		3
93	Expression of Presenilin 1 in nervous system during rat development. Journal of Comparative Neurology, 1999, 410, 556-570.	1.6	3
94	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. SSRN Electronic Journal, 0, , .	0.4	3
95	Identification of Protein Kinases That Modify Specific Epitopes. Analytical Biochemistry, 1994, 223, 159-161.	2.4	2
96	Editorial: Untangling the Role of Tau in Physiology and Pathology. Frontiers in Aging Neuroscience, 2020, 12, 146.	3.4	2
97	The Dimensional Structure of Subjective Cognitive Decline. Neuromethods, 2018, , 45-62.	0.3	2
98	Tau Phosphorylation as a Therapeutic Target in Alzheimerâ€™s Disease. , 2016, , 327-341.		1
99	Neuroanatomical signature of superâ€ageing: Structural brain study of youthful episodic memory in people over the age of 80. Alzheimer's and Dementia, 2020, 16, e041915.	0.8	1
100	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0
101	Recent developments in tau-based therapeutics for Alzheimerâ€™s disease and related dementsia. SpringerPlus, 2015, 4, L14.	1.2	0
102	APOEâ€îµ4 and hippocampal volume in the cognitively healthy elderly: Longitudinal analysis reveals origins of apparent crossâ€sectional differences. Alzheimer's and Dementia, 2020, 16, e042680.	0.8	0
103	Induction of an Immune Response to Transmissible Gastroenteritis Coronavirus Using Vectors with Enteric Tropism. Advances in Experimental Medicine and Biology, 1994, 342, 455-462.	1.6	0
104	A Novel Gene in the Armadillo Family Interacts with Presenilin 1. , 1998, , 171-180.		0